From ultra-flexible materials redefining brain-computer interfaces (BCIs) to record-shattering global out-licensing deals, China’s biopharmaceutical sector is undergoing a profound qualitative transformation. ShanghaiEye takes you inside the Yunfan Future Factory and the cross-discipline innovation hub hosted by Chia Tai Tianqing (CTTQ)—a subsidiary of top-50 global pharma giant Sino Biopharmaceutical—to explore the cutting-edge ecosystem driving the future of global healthcare.

We examine a breakthrough BCI technology developed in Shanghai: an ultra-flexible photoresist material for neural electrode arrays. Ye Tianyang, CEO and Co-Founder of Yunfan Future, explains how this material—engineered to be 1,000 times softer than the rigid alternatives utilized by Western counterparts like Elon Musk’s Neuralink—exponentially reduces tissue damage and immune rejection. With dozens of human clinical trials already successfully completed worldwide, this innovation highlights the immense strength of Shanghai’s local talent pool and medical device supply chain.

The feature also spotlights the strategic roadmap of China’s pharmaceutical leaders. Eric Tse, CEO of Sino Biopharmaceutical and Chairman of CTTQ, breaks down their vision to build an open, interdisciplinary incubator. This global nexus bridges experts, scholars, and upstream and downstream partners, transforming Shanghai into a premier launchpad for international innovative drugs. Furthermore, Mr. Tse discusses the \.